ClinicalTrials.gg
Status unknownNCT05193201Updated Jan 14, 2022

A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

A Phase 1 interventional study of recombinant human thrombopoietin injection in Liver Disease Chronic and Thrombocytopenia, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-14.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing recombinant human thrombopoietin in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. recombinant human thrombopoietin · Thrombocytopenia.

Planned enrollment
13th of 18
54 · median 70
Started
2022
with 3 others
Phase 1
2 of 18
none open now
Registered
10th of 18
by date

Among the 18 studies testing recombinant human thrombopoietin in Thrombocytopenia, this one is the 13th largest by planned enrollment, is one of 4 that started in 2022, is one of 2 in phase 1, and was the 10th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 18 studies testing recombinant human thrombopoietin in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About recombinant human thrombopoietin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing recombinant human thrombopoietin in Thrombocytopenia, or all of them as a file.
02

Study summary

The purpose of this study is to explore the multiple-dose regimen of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

Read the detailed description

This is a multi-center, open label, phase Ib clinical study. The effectiveness of the multiple-dose regimen of recombinant human thrombopoietin injection in the treatment of thrombocytopenia in patients with chronic liver disease is mainly verified by evaluating the proportion of responders with platelet count in the first 8 days after treatment. Cohort 1 (n=18) : 50*10\^9/L ≤ Baseline of PLT \< 75*10\^9/L. Cohort 2 (n=36) : 30*10\^9/L ≤ Baseline of PLT \< 50*10\^9/L.

03

Conditions studied

  • Liver Disease Chronic
  • Thrombocytopenia

Browse trials for

Keywords

  • recombinant human thrombopoietin injection
  • Thrombocytopenia
  • Liver Disease Chronic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender: There is no limit to men and women.
  • 18 years old to 75 years old.
  • Liver cirrhosis diagnosed by /imaging due to chronic liver disease, and classification is A and B. Patients with liver cirrhosis diagnosed by transient elastography technology can also be included in the group.
  • Baseline level: 30×10\^9/L≤platelet count\<75×10\^9/L.
  • Liver function and aspartate aminotransferase (AST)≤5×, total ≤1.5×ULN, blood creatinine≤1.5×ULN.
  • Able to understand and be willing to comply with the requirements of the clinical trial protocol, and voluntarily sign a written form.

Exclusion criteria

Exclusion Criteria:

  • Those who are known to be allergic to any component of this product.
  • Patients with liver cirrhosis caused by drug-induced liver damage.
  • Those with a history of splenectomy or liver transplantation.
  • Previously or currently suffering from serious diseases of any organ or system other than the liver, including cardiovascular disease, blood system disease, and nervous system disease patients, as well as any other diseases judged by the investigator to be unsuitable for participating in this trial.
  • Currently suffering from malignant tumors, including solid tumors and hematological .
  • Those who are clearly diagnosed as liver failure.
  • Liver cirrhosis with serious complications, including: hepatic encephalopathy, ascites, upper gastrointestinal bleeding, etc.;.
  • People who have previously or are currently suffering from any disease that may lead to reduced count and/or abnormal platelet function except for chronic liver disease and cirrhosis, including aplastic anemia, myelodysplastic syndrome, myelofibrosis, etc.
  • Those who have undergone intrahepatic portosystemic shunt via jugular vein in the past.
  • Doppler ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI) and other imaging examinations that indicate the presence of portal vein thrombosis within 28 days before administration.
  • Use heparin, warfarin, non-steroidal anti-inflammatory drugs, aspirin, verapamil, and ticlopidine or glycoprotein IIb/IIIa antagonist (such as tirofiban) within 7 days before administration treat.
  • Interferon has been used within 14 days before administration.
  • Have received platelet transfusion or used platelet-containing blood products within 14 days before administration, except for transfusion of concentrated red blood cells.
  • Those who have received any platelet-increasing therapy within 28 days before administration (the platelet-increasing function of Li Kejun, caffeic acid tablets and/or certain Chinese medicines or Chinese patent medicines that have the function of increasing platelet function can be accepted within 14 days), including but not Limited to rhTPO.
  • No more than 28 days after the cessation of other research drug treatments or device research treatments carried out before the administration.
  • There are currently patients with WHO ≥ Grade 2 active bleeding, or those with active bleeding in the past 2 weeks.
  • Known positive or Treponema pallidum antibody positive.
  • Combined with severe infections that cannot be effectively controlled (except for chronic and chronic ).
  • The subjects did not agree to take effective measures during the trial period. The female subjects had a positive blood pregnancy test during the screening period; women who were pregnant or breastfeeding or had pregnancy plans within 3 months.
  • Subjects' understanding, communication and cooperation are not enough to guarantee that the research will be carried out in accordance with the protocol.
  • The researcher believes that the subjects are not suitable to participate in this study due to other reasons.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L

    The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

    Drug: recombinant human thrombopoietin injection

  • Experimental
    Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.

    The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

    Drug: recombinant human thrombopoietin injection

Interventions

06

What researchers measure

Primary outcomes

  1. the proportion of responders with platelet count

    Based on the results of routine blood tests, calculate the proportion of responders with platelet counts in the first 8 days after treatment

    Time frame: Up to 8 days

Secondary outcomes

  1. the proportion of responders with platelet count

    Based on the results of routine blood tests, calculate the proportion of responders with platelet counts during the study

    Time frame: Up to 36 days

  2. Platelet count

    Based on the results of routine blood tests, calculate the change in platelet count from baseline at different visit times after treatment. Calculate the duration of alleviation of thrombocytopenia symptom relief to different levels (≥50×10\^9/L; ≥75×10\^9/L; ≥100×10\^9/L).

    Time frame: Up to 36 days

  3. Platelet peak

    Based on the results of routine blood tests, observe the peak value of platelets and record the peak time after treatment.

    Time frame: Up to 36 days

  4. AE

    All adverse events related to rhTPO observed through various tests (including blood routine, liver function, pregnancy test, electrocardiogram, etc.)

    Time frame: Up to 36 days

  5. Immunogenicity of rhTPO

    Detect the presence of anti-rhTPO antibodies through the subject's blood sample

    Time frame: At Day 1, Day 14, Day 36

  6. Cmax

    Detect the blood concentration of rhTPO by the subject's blood sample

    Time frame: Up to 36 days

  7. AUC

    Detect the blood concentration of rhTPO by the subject's blood sample, then calculate the area under the curve (AUC)

    Time frame: Up to 36 days

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing 100034, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2022; primary completion for Oct 2022, 9 months later.

Of 18 phase 1 interventional studies under Thrombocytopenia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2021
First posted
Jan 14, 2022
StartEst.
Jan 16, 2022
Primary completionEst.
Oct 16, 2022
CompletionEst.
Dec 31, 2022
Last update
Jan 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05193201
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Jan 16, 2022 (estimated)
Primary completion
Oct 16, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Jan 14, 2022

Study contacts

Gang Tong, MD
Contact
tonggang@3sbio.com
021-60970099
Yimin Cui, PhD
principal investigator · Peking University First Hospital
Xiaoyuan Lin, Master
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant human thrombopoietin

Start the discussion